Treatment studies, BMJ series on China’s response to COVID-19, transmission routes, Omicron and reinfection

Peer reviewed journals featured:

- Systematic reviews on:
  - Immunogenicity of COVID-19 vaccines in patients with haematological malignancy [here]
  - Effectiveness of remdesivir, lopinavir/ritonavir, and favipiravir for treating COVID-19 [here]
  - Combination therapy of tocilizumab and steroid for COVID-19 patients [here]
- Randomised clinical trials of:
  - Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR) [here]
  - Favipiravirin in high-risk COVID-19 patients [here]
  - Sofosbuvir and daclatasvir in hospitalised COVID-19 patients (DISCOVER) [here]
- Observational studies on:
  - COVID-19 vaccine effectiveness in New York State [here]
  - Comparative effectiveness of Comirnaty (Pfizer) and Spikevax (Moderna) vaccines in US veterans [here]
  - SARS-CoV-2 transmission in schools in Korea [here]
- A BMJ series on China’s response to COVID-19:
  - The role of asymptomatic and presymptomatic infections [here]
  - Importance of public health tools in emerging infectious diseases [here]
  - Non-pharmaceutical interventions during the rollout of COVID-19 vaccines [here]
  - Effectiveness of 14-day quarantine strategy [here]
  - Use of contact tracing, isolation, and mass testing to control transmission [here]
  - Cold chain logistics as a potential mode of SARS-CoV-2 transmission [here]
- Commentary on:
  - SARS-CoV-2 transmission routes and mitigations [here] and the development of an associated interactive graphic [here]

Letters and correspondence discussed:

- Viral dynamics of SARS-CoV-2 variants in vaccinated and unvaccinated persons [here]
- US state-level legal interventions related to COVID-19 vaccine mandates [here]
Pre-peer review articles featured:

- Effectiveness and durability of protection against future SARS-CoV-2 infection conferred by COVID-19 vaccination and previous infection [here](#).
- Clinical outcomes associated with subcutaneous or intravenous administration of casirivimab and imdevimab monoclonal antibodies in COVID-19 [here](#).
- Tajima D test accurately forecasts Omicron / COVID-19 outbreak [here](#).
- Increased risk of SARS-CoV-2 reinfection associated with the emergence of the Omicron variant in South Africa [here](#).

News and blogs

- The UK approves monoclonal antibody sotrovimab for over 12s at high risk [here](#).
- The FDA expert panel recommends authorising molnupiravir but also voices concern [here](#).
- Omicron is supercharging the COVID-19 vaccine booster debate [here](#).
- A tale of two antiviral targets and the COVID-19 drugs that bind them [here](#).
- What scientists know so far about Omicron [here](#).
- Omicron-variant border bans ignore the evidence [here](#).

[Click here](#) to subscribe to the daily evidence digest.

---

**Living Evidence Tables**

Living Evidence tables are up-to-date summaries of emerging evidence. Tables are available on [COVID-19 transmission](#), SARS-CoV-2 [vaccines](#), and [variants](#) of concern, [post-acute sequelae of COVID-19 (PASC)](#), [surgery and COVID-19](#), [rapid testing](#) and [risk mitigation strategies](#).